To provide a new breast cancer diagnostic and therapeutic method of using protein as a molecule marker, by quantitatively identifying protein singularly or very excessively developed in a breast cancer cell line and protein indicating increased expression and reduced expression.
This breast cancer diagnostic method is characterized by diagnosing breast cancer by using specific protein varied in the expression in a human breast cancer cell line identified by proteome analysis as the molecule marker, by using a fluorescent derivatization-liquid chromatography tandem mass spectrometry (FD-LC-MS/MS). The breast cancer diagnostic method is characterized by diagnosing the breast cancer by using galectin-1 and annexin-2 or thiodrexin-1, or annexin-2 and EF-TU, or peroxiredoxin-1 and RanGAP as the molecule marker and using a pair of galectin-1 and/or annexin-2 and tropomyosin-1 as the molecule marker. This invention can provide the new breast cancer diagnostic and therapeutic method.
ICHIBANGASE TOMOKO
SAITO RYOICHI
| JP2008502891A | 2008-01-31 | |||
| JP2005017264A | 2005-01-20 | |||
| JP2006508326A | 2006-03-09 |
JPN6013031917; ＣＨＵＴＨＡＰＩＳＩＴＨ，Ｓ． 他: '"Ｐｒｏｔｅｏｍｉｃ ｐｒｏｆｉｌｉｎｇ ｏｆ ＭＣＦ-７ ｂｒｅａｓｔ ｃａｎｃｅｒ ｃｅｌｌｓ ｗｉｔｈ ｃｈｅｍｏｒｅｓｉｓｔａｎｃｅ ｔｏ ｄｉｆｆｅｒｅｎｔ ｔｙｐｅｓ ｏｆ ａｎｔｉ-ｃ' Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｊｏｕｒｎａｌ ｏｆ Ｏｎｃｏｌｏｇｙ Ｖｏｌｕｍｅ ３０， Ｎｕｍｂｅｒ ６, 200706, Ｐａｇｅｓ １５４５-１５５１
JPN6013031919; ＺＨＵ，Ｓ． 他: '"ＭｉｃｒｏＲＮＡ-２１ Ｔａｒｇｅｔｓ ｔｈｅ Ｔｕｍｏｒ Ｓｕｐｐｒｅｓｓｏｒ Ｇｅｎｅ Ｔｒｏｐｏｍｙｏｓｉｎ １ （ＴＰＭ１）"' Ｔｈｅ Ｊｏｕｒｎａｌ ｏｆ Ｂｉｏｌｏｇｉｃａｌ Ｃｈｅｍｉｓｔｒｙ Ｖｏｌｕｍｅ ２８２, 200703, Ｐａｇｅｓ １４３２８-１４３３６
Next Patent: MEASURING DEVICE OF OPTICAL SURFACE PROPERTY OF WORKPIECE